Larimar Therapeutics Inc (LRMR)
Healthcare
Biotechnology
4.00 $
+4.2%
vs. previous close
Closing price · As of: 3. Aug 2026
Larimar Therapeutics Inc (LRMR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -45 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.4 | -9.2 | -9.3 | -10 | -14 | -25 | -22 | -27 | -19 | -29 | -39 | -45 | -131 | |
| 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | -0.7 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | |
| 2.0 | 1.8 | 1.9 | 2.1 | 2.3 | 2.0 | 2.4 | 1.8 | 1.8 | 1.8 | 1.6 | 2.0 | 7.1 | |
| 2.0 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -1.1 | -1.5 | 2.3 | 2.7 | 7.1 | -9.3 | 5.8 | 1.6 | 5.4 | 17 | 23 | -17 | 29 | |
| 0.0 | 0.0 | 0.2 | 0.0 | 0.3 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -9.8 | -46 | -2.6 | -68 | -63 | 27 | 19 | 14 | 19 | 33 | 34 | 29 | 115 | |
| – | – | – | – | -0.3 | 0.3 | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 0.0 | 162 | -0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 65 | -0.2 | 108 | 173 | |
| -17 | -56 | -12 | 83 | -78 | 2.8 | -2.6 | -12 | -0.5 | 70 | -4.7 | 93 | 157 | |
| -7.4 | -9.2 | -9.5 | -10 | -14 | -25 | -22 | -27 | -19 | -29 | -39 | -45 | -131 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.